13 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp08351 | Seq ID No. 15 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVTSVIK | Synthetic | Not Available | Tetrazolium-based assay | HOP-062 | Lung Cancer | Cell viability ~ 50% at 20 μM |
| dbacp08352 | Seq ID No. 15 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVTSVIK | Synthetic | Not Available | Tetrazolium-based assay | NCI-H460 | Lung Cancer | Cell viability < 25% at 20 μM |
| dbacp08353 | Seq ID No. 15 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVTSVIK | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability < 50% at 20 μM |
| dbacp08354 | Seq ID No. 16 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKSVIK | Synthetic | Not Available | Tetrazolium-based assay | HOP-062 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08355 | Seq ID No. 16 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKSVIK | Synthetic | Not Available | Tetrazolium-based assay | NCI-H460 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08356 | Seq ID No. 16 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKSVIK | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08357 | Seq ID No. 17 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKKVIK | Synthetic | Not Available | Tetrazolium-based assay | HOP-062 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08358 | Seq ID No. 17 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKKVIK | Synthetic | Not Available | Tetrazolium-based assay | NCI-H460 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08359 | Seq ID No. 17 from patent ID US202000079827A1 | LKKWWKKVKGLLGGLLGKVKKVIK | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08360 | Seq ID No. 26 from patent ID US202000079827A1 | RRWVRRVRRVWRRVVRVVRRWVRR | Synthetic | Not Available | Tetrazolium-based assay | H-460 | Lung Cancer | Cell viability < 50% at 20 μM |
| dbacp08361 | Seq ID No. 26 from patent ID US202000079827A1 | RRWVRRVRRVWRRVVRVVRRWVRR | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability > 50% at 20 μM |
| dbacp08362 | Seq ID No. 34 from patent ID US202000079827A1 | RRWvRRvRRvWRRvvRvvRRWvRR | Synthetic | Not Available | Tetrazolium-based assay | NCI-H460 | Lung Cancer | Cell viability < 25% at 20 μM |
| dbacp08363 | Seq ID No. 34 from patent ID US202000079827A1 | RRWvRRvRRvWRRvvRvvRRWvRR | Synthetic | Not Available | Tetrazolium-based assay | Calu-1 | Lung Cancer | Cell viability > 50% at 20 μM |